Mayo Clinic | Strategic Alliance Partners

Latest from Mayo Clinic

Mayo Clinic Researchers Identify Proteins Linked to Immunotherapy Resistance in Metastatic Colorectal Cancer

March 14, 2025

Article

A discovery by researchers from Mayo Clinic may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer.

Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL

March 13, 2025

Video

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in relapsed/refractory LBCL.

Advanced Therapies and Innovative Options for Prostate Cancer Care

February 13, 2025

Article

Multidisciplinary treatment addresses all facets of patient health, resulting in personalized prostate cancer treatment plans that optimize outcomes.

Other Key Follicular Lymphoma Data From ASH 2024

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.

Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.

2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.

CD19 Expression Loss and Tafasitamab in R/R DLBCL

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.

Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.

The Phase 3 inMIND Trial: Tafasitamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.

Highlighting Key CML/ALL Data Presented at ASH 2024

January 23, 2025

Video

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.

Selecting a TKI in Subsequent Lines of Therapy in CML

January 23, 2025

Video

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.

The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL

January 23, 2025

Video

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

Dosing Strategies for Ponatinib in CML and ALL

January 23, 2025

Video

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.

Emerging Mutation Analysis from the OPTIC Trial

January 23, 2025

Video

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial

January 23, 2025

Video

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

January 20, 2025

Podcast

Dr Dronca discusses the FDA approval of subcutaneous nivolumab and hyaluronidase for advanced or metastatic solid tumors.

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups

January 15, 2025

Article

Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.

Researchers Resolve Uncertainty in BRCA2 Testing, Improving Cancer Risk Assessment and Patient Care

January 14, 2025

Article

Findings will help identify patients with breast, ovarian, pancreatic, or prostate cancer who may benefit from targeted therapies.

FDA Approval of Subcutaneous Nivolumab Represents Paradigm Shift in Solid Tumor Management

January 13, 2025

Article

Roxana S. Dronca, MD, discusses the FDA approval of subcutaneous nivolumab across solid tumor indications.

Advances in PV Management Increase Hepcidin Levels and Improve Disease Burden

January 13, 2025

Article

Naseema Gangat, MBBS, discusses the role of rusfertide for decreasing phlebotomy needs and the potential future for disease-modifying PV management.